255 related articles for article (PubMed ID: 17229838)
1. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes.
Bozzacco L; Trumpfheller C; Siegal FP; Mehandru S; Markowitz M; Carrington M; Nussenzweig MC; Piperno AG; Steinman RM
Proc Natl Acad Sci U S A; 2007 Jan; 104(4):1289-94. PubMed ID: 17229838
[TBL] [Abstract][Full Text] [Related]
2. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine.
Trumpfheller C; Finke JS; López CB; Moran TM; Moltedo B; Soares H; Huang Y; Schlesinger SJ; Park CG; Nussenzweig MC; Granelli-Piperno A; Steinman RM
J Exp Med; 2006 Mar; 203(3):607-17. PubMed ID: 16505141
[TBL] [Abstract][Full Text] [Related]
3. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.
Idoyaga J; Lubkin A; Fiorese C; Lahoud MH; Caminschi I; Huang Y; Rodriguez A; Clausen BE; Park CG; Trumpfheller C; Steinman RM
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2384-9. PubMed ID: 21262813
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
[TBL] [Abstract][Full Text] [Related]
5. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
6. HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC.
Bozzacco L; Trumpfheller C; Huang Y; Longhi MP; Shimeliovich I; Schauer JD; Park CG; Steinman RM
Eur J Immunol; 2010 Jan; 40(1):36-46. PubMed ID: 19830741
[TBL] [Abstract][Full Text] [Related]
7. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
[TBL] [Abstract][Full Text] [Related]
8. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
[TBL] [Abstract][Full Text] [Related]
9. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
[TBL] [Abstract][Full Text] [Related]
10. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
Birkholz K; Schwenkert M; Kellner C; Gross S; Fey G; Schuler-Thurner B; Schuler G; Schaft N; Dörrie J
Blood; 2010 Sep; 116(13):2277-85. PubMed ID: 20566893
[TBL] [Abstract][Full Text] [Related]
11. Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes.
Graham JP; Authie P; Yu CI; Zurawski SM; Li XH; Marches F; Flamar AL; Acharya A; Banchereau J; Palucka AK
Vaccine; 2016 Sep; 34(41):4857-4865. PubMed ID: 27595442
[TBL] [Abstract][Full Text] [Related]
12. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.
Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F
J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703
[TBL] [Abstract][Full Text] [Related]
13. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.
Cruz LJ; Tacken PJ; Pots JM; Torensma R; Buschow SI; Figdor CG
Biomaterials; 2012 Jun; 33(16):4229-39. PubMed ID: 22410170
[TBL] [Abstract][Full Text] [Related]
15. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination.
Bonifaz LC; Bonnyay DP; Charalambous A; Darguste DI; Fujii S; Soares H; Brimnes MK; Moltedo B; Moran TM; Steinman RM
J Exp Med; 2004 Mar; 199(6):815-24. PubMed ID: 15024047
[TBL] [Abstract][Full Text] [Related]
16. Targeting DEC-205
Tabansky I; Keskin DB; Watts D; Petzold C; Funaro M; Sands W; Wright P; Yunis EJ; Najjar S; Diamond B; Cao Y; Mooney D; Kretschmer K; Stern JNH
Mol Med; 2018 May; 24(1):17. PubMed ID: 30134798
[TBL] [Abstract][Full Text] [Related]
17. A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation.
Schjetne KW; Thompson KM; Aarvak T; Fleckenstein B; Sollid LM; Bogen B
Int Immunol; 2002 Dec; 14(12):1423-30. PubMed ID: 12456590
[TBL] [Abstract][Full Text] [Related]
18. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
19. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody.
Cheong C; Choi JH; Vitale L; He LZ; Trumpfheller C; Bozzacco L; Do Y; Nchinda G; Park SH; Dandamudi DB; Shrestha E; Pack M; Lee HW; Keler T; Steinman RM; Park CG
Blood; 2010 Nov; 116(19):3828-38. PubMed ID: 20668230
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.
Trumpfheller C; Longhi MP; Caskey M; Idoyaga J; Bozzacco L; Keler T; Schlesinger SJ; Steinman RM
J Intern Med; 2012 Feb; 271(2):183-92. PubMed ID: 22126373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
